Atlas Venture Life Science Advisors, LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 12, 2025), Atlas Venture Life Science Advisors, LLC reported 11 stock positions worth $662.4 million. Its top holding was Kymera Therapeutics (KYMR) at 32.3% of the portfolio, followed by Disc Medicine (IRON, 19.1%) and Dyne Therapeutics (DYN, 13.1%). Compared with Q1 2025, it sold out of 2. The biggest sale was an exit from Aerovate Therapeutics.
- Most Recent 13F
- Q2 2026
- Location
- CAMBRIDGE, MA
- CIK
- 0001917529
- Portfolio Value
- $662.4M (Q2 2025)
- SEC Filing
- 0001104659-25-076898 ↗ filed Aug 12, 2025
Holdings Value
Holdings 11 stocks · $662.4M
| KYMR Kymera Therapeutics Inc. | 32.26% | 4,896,462 | $213.7M | No change |
| IRON Disc Medicine Inc. | 19.07% | 2,384,456 | $126.3M | No change |
| DYN Dyne Therapeutics Inc. | 13.12% | 9,130,465 | $86.9M | No change |
| SION Sionna Therapeutics Inc. | 9.68% | 3,694,020 | $64.1M | No change |
| THRD Third Harmonic Bio Inc. | 8.53% | 10,402,286 | $56.5M | No change |
| VIGL Vigil Neuroscience Inc. | 7.01% | 5,836,874 | $46.4M | No change |
| DAWN Day One Biopharmaceuticals I | 6.31% | 6,430,257 | $41.8M | No change |
| KRRO Korro Bio Inc. | 2.14% | 1,137,149 | $14.2M | No change |
| IKENA ONCOLOGY INC | 1.02% | 5,018,178 | $6.7M | No change |
| QTTB Q32 Bio Inc. | 0.47% | 2,092,106 | $3.1M | No change |
| GBIO Generation Bio Co. | 0.40% | 8,279,484 | $2.7M | No change |
Portfolio Sells Q1 2025 → Q2 2025
| AEROVATE THERAPEUTICS INC | Sold out | 0.00% | −0.87 |
| SPRO Spero Therapeutics Inc. | Sold out | 0.00% | −0.04 |
Portfolio Buys Q1 2025 → Q2 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 7 | $881.3M | KYMR, DYN, SION, KLRA, IRON |
| Q1 2026 | 6 | $790.0M | KYMR, DYN, SION, IRON, QTTB |
| Q4 2025 | 8 | $865.2M | KYMR, DYN, SION, IRON, DAWN |
| Q3 2025 | 9 | $752.6M | KYMR, IRON, DYN, SION, KRRO |
| Q2 2025 | 11 | $662.4M | KYMR, IRON, DYN, SION, THRD |
| Q1 2025 | 13 | $521.8M | KYMR, IRON, DYN, DAWN, SION |
| Q4 2024 | 13 | $819.7M | KYMR, DYN, IRON, THRD, DAWN |
| Q3 2024 | 14 | $1.1B | DYN, KYMR, THRD, IRON, QTTB |
| Q2 2024 | 15 | $949.6M | DYN, KYMR, THRD, IRON, DAWN |
| Q1 2024 | 16 | $1.1B | DYN, KYMR, IRON, DAWN, THRD |